Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa
2011

Pre-treatment Mortality in HIV Patients in The Gambia

Sample size: 790 publication Evidence: high

Author Information

Author(s): Toyin Togun, Ingrid Peterson, Shabbar Jaffar, Francis Oko, Uduak Okomo, Kevin Peterson, Assan Jaye

Primary Institution: Medical Research Council - The Gambia Unit

Hypothesis

What is the pre-treatment mortality rate and its predictors among ART-eligible adult patients in a West Africa clinic-based cohort?

Conclusion

A high proportion of ART-eligible patients did not start treatment, and the pre-treatment mortality rate was significant among HIV-infected patients in the cohort.

Supporting Evidence

  • 64.6% of ART-eligible patients started treatment.
  • 21.9 deaths per 100 person-years was the pre-treatment mortality rate.
  • 40% of patients lost to follow-up cited difficulty with disclosing their HIV status as a reason for not starting ART.

Takeaway

Many people who could get HIV treatment didn't start it, and a lot of them died before they could. This shows that we need to help them get treatment faster.

Methodology

The study included all HIV-infected patients aged 15 years or older eligible for ART from June 2004 to September 2009, using Kaplan-Meier estimates and Cox proportional hazard models for analysis.

Potential Biases

Potential bias due to the requirement of disclosing HIV status before starting ART, which may deter patients from initiating treatment.

Limitations

The study may underestimate pre-treatment mortality due to patients lost to follow-up who could not be traced.

Participant Demographics

The median age was 37 years, with 68.2% female, and included 81.9% HIV-1, 13.0% HIV-2, and 5.1% dually infected patients.

Statistical Information

P-Value

<0.001

Confidence Interval

95% CI 18.3 - 26.2

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1742-6405-8-24

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication